Perspective Therapeutics (NYSE:CATX) Price Target Lowered to $16.00 at Royal Bank of Canada

Perspective Therapeutics (NYSE:CATX) had its price objective reduced by research analysts at Royal Bank of Canada from $25.00 to $16.00 in a report issued on Monday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Royal Bank of Canada’s target price indicates a potential upside of 300.00% from the stock’s previous close.

Other analysts have also recently issued reports about the company. UBS Group began coverage on Perspective Therapeutics in a report on Thursday, October 24th. They issued a “buy” rating and a $20.00 target price on the stock. Wedbush reissued an “outperform” rating and issued a $11.00 price objective (down from $20.00) on shares of Perspective Therapeutics in a research note on Thursday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Perspective Therapeutics in a research note on Monday, September 9th. Oppenheimer dropped their price target on Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating on the stock in a research note on Friday. Finally, Truist Financial assumed coverage on shares of Perspective Therapeutics in a research report on Wednesday, September 25th. They set a “buy” rating and a $21.00 target price on the stock. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $15.14.

Perspective Therapeutics Price Performance

CATX stock traded up $0.53 during trading on Monday, reaching $4.00. 1,691,214 shares of the company were exchanged, compared to its average volume of 800,430. The business’s 50-day moving average is $11.52. Perspective Therapeutics has a twelve month low of $2.28 and a twelve month high of $19.05.

Perspective Therapeutics (NYSE:CATX) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.21) earnings per share for the quarter, hitting the consensus estimate of ($0.21). Perspective Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,096.66%. The company had revenue of $0.37 million for the quarter. On average, equities research analysts anticipate that Perspective Therapeutics will post -0.86 EPS for the current fiscal year.

Institutional Investors Weigh In On Perspective Therapeutics

Several hedge funds have recently bought and sold shares of CATX. nVerses Capital LLC purchased a new position in shares of Perspective Therapeutics during the third quarter worth approximately $57,000. US Bancorp DE boosted its holdings in Perspective Therapeutics by 142.7% during the 3rd quarter. US Bancorp DE now owns 6,576 shares of the company’s stock valued at $88,000 after acquiring an additional 3,866 shares during the period. Victory Capital Management Inc. bought a new position in shares of Perspective Therapeutics in the second quarter worth approximately $117,000. Point72 DIFC Ltd bought a new position in shares of Perspective Therapeutics during the second quarter valued at about $118,000. Finally, Intech Investment Management LLC purchased a new position in Perspective Therapeutics during the 3rd quarter valued at about $137,000. 54.66% of the stock is currently owned by institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.